{"title":"在一名原发性肝癌患者身上联合应用中药瑞伐替尼和卡瑞珠单抗：病例报告和文献综述","authors":"Yan Zhu, Yaoshui Lai, Hongjie Song","doi":"10.1002/acm4.20","DOIUrl":null,"url":null,"abstract":"<p>The patient was diagnosed with primary liver cancer featuring intrahepatic metastasis (Barcelona stage B; Stage IIB), hepatitis B infection, and post-hepatitis B cirrhosis during the period of compensated liver function. Following a 7-month regimen combining traditional Chinese herbal medicine (TCHM) with Renvatinib and Carrelizumab, the patient exhibited favorable tolerability, no bleeding risks, and stable tumor progression. The effectiveness of TCHM in this case was marked by significant symptom alleviation, reduced serum molecular markers, minimized adverse reactions, and obviated surgical intervention. Blood tests displayed alpha-fetoprotein levels ranging from 8.85 to 20.65 IU/mL, with no increase in bleeding risks.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 2","pages":"128-135"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.20","citationCount":"0","resultStr":"{\"title\":\"Combined application of the traditional Chinese herbal medicine, Renvatinib, and Carrelizumab in a patient with primary liver cancer: A case report and literature review\",\"authors\":\"Yan Zhu, Yaoshui Lai, Hongjie Song\",\"doi\":\"10.1002/acm4.20\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The patient was diagnosed with primary liver cancer featuring intrahepatic metastasis (Barcelona stage B; Stage IIB), hepatitis B infection, and post-hepatitis B cirrhosis during the period of compensated liver function. Following a 7-month regimen combining traditional Chinese herbal medicine (TCHM) with Renvatinib and Carrelizumab, the patient exhibited favorable tolerability, no bleeding risks, and stable tumor progression. The effectiveness of TCHM in this case was marked by significant symptom alleviation, reduced serum molecular markers, minimized adverse reactions, and obviated surgical intervention. Blood tests displayed alpha-fetoprotein levels ranging from 8.85 to 20.65 IU/mL, with no increase in bleeding risks.</p>\",\"PeriodicalId\":100029,\"journal\":{\"name\":\"Advanced Chinese Medicine\",\"volume\":\"1 2\",\"pages\":\"128-135\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.20\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Chinese Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acm4.20\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Chinese Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acm4.20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Combined application of the traditional Chinese herbal medicine, Renvatinib, and Carrelizumab in a patient with primary liver cancer: A case report and literature review
The patient was diagnosed with primary liver cancer featuring intrahepatic metastasis (Barcelona stage B; Stage IIB), hepatitis B infection, and post-hepatitis B cirrhosis during the period of compensated liver function. Following a 7-month regimen combining traditional Chinese herbal medicine (TCHM) with Renvatinib and Carrelizumab, the patient exhibited favorable tolerability, no bleeding risks, and stable tumor progression. The effectiveness of TCHM in this case was marked by significant symptom alleviation, reduced serum molecular markers, minimized adverse reactions, and obviated surgical intervention. Blood tests displayed alpha-fetoprotein levels ranging from 8.85 to 20.65 IU/mL, with no increase in bleeding risks.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
